Justin Balko Archives
Dec. 22, 2020—by Tom Wilemon A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center. The researchers demonstrated that the drug abatacept reduced...
Apr. 23, 2020—Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.
Dec. 5, 2019—Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...
May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.
Apr. 21, 2016—A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.